Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-09-06
2011-11-01
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
08048431
ABSTRACT:
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.
REFERENCES:
patent: 2003/0044421 (2003-03-01), Emini et al.
patent: 2003/0096778 (2003-05-01), Shiver et al.
patent: 2007/0178562 (2007-08-01), Haynes et al.
patent: 2003-523188 (2003-08-01), None
patent: WO 01/60838 (2001-08-01), None
Wang, L.-X., 2003, Bioorganic Approaches Towards HIV Vaccine Design, Curr. Pharm. Des. 9:1771-1787.
Gallo, R. C., 2005, The End or the Beginning of the Drive to an HIV-Preventive Vaccine: a View From Over 20 Years, The Lancet, 366(9500):1894-1898.
Walker, B. D., and D. R. Burton, 2008, Toward an AIDS Vaccine, Science 320:760-764.
Levine, a. J., 2008, Why Do We Not Yet Have a Human Immunodeficiency Virus Vaccine? J. Virol. 82(24):11998-12000.
Supplementary Partial European Search Report dated Aug. 1, 2008—EP Appln. No. 04 78 4298.
Gaschen et al, “Diversity Considerations in HIV-1 Vaccine Selection”, Science 296 (5577):2354-2360 (2003).
Nickle et al, “Consensus and Ancestral State HIV Vaccines”, Science 299(5612):1515-1518 (2003).
International Search Report issued in connection with PCT/US04/30397 dated Mar. 8, 2005.
Supplementary Partial European Search Report issued in connection with EP 04 78 4298 dated Aug. 1, 2008.
Gao et al., “Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity”, Expert Rev. Vaccines 3(4):S161-168 (2004).
Liao et al., “A Group M Consensus Envelope Glycoprotein induces Antibodies That Neutralize Subsets of Subtype B and C HIV-1 Primary Viruses,” NIH Public Access, pp. 1-30, Published in final edited form as Virology 353(2):268-282 (2006).
Leitner, T. et al., eds., “HIV Sequence Compendium 2003”; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, LA-UR No. 04-7420, pp. 513-573 and attached appendix.
Morris et al., “Characterization and selection of HIV-1 subtype C isolates for use in vaccine development”, AIDS Res Hum Retroviruses., 19(2):133-44 (2003)—Abstract.
Novitsky et al., “Human Immunodeficiency Vrius Type 1 Subtype C Molecular Phylogeny: Consensus Sequence for an AIDS Vaccine Design?”, Journal of Virology, vol. 76, No. 11, pp. 5435-5451 (2002).
Ellenberger et al., “Generation of a Consensus Sequence from Prevalent and Incident HIV-1 Infections in West Africa to Guide AIDS Vaccine Development1,2”, Virology 302, pp. 155-163 (2002).
Demi et al., “Multiple Effects of Codon Usage Optimization on Expression and Immunogenicity of DNA Candidate Vaccines Encoding the Human Immunodeficiency Virus Type 1 Gag Protein”, Journal of Virology, vol. 75, No. 22 pp. 10991-11001 (2001).
Gao et al., “Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice”, AIDS Res Hum Retroviruses, 19(9):817-23 (2003)—Abstract.
Williamson et al, “Characterization and selection of HIV-1 subtype C isolates for use in vaccine development”, AIDS Res. Hum. Retroviruses 19(2):133-144 (2003)—Abstract.
Kofman et al, “HIV-1 gag expression is quantitatively dependent on the ratio of native and optimized codons”, Tsitologiia 45(1):86-93 (2003)—Abstract.
Office Action dated Nov. 30, 2009 in U.S. Appl. No. 10/572,638.
Office Action dated Jun. 4, 2010 in U.S. Appl. No. 10/572,638.
Notice of Allowance dated Jan. 4, 2011 in U.S. Appl. No. 10/572,638.
Notice of Allowance dated May 12, 2011 in U.S. Appl. No. 10/572,638.
Duke University
Nixon & Vanderhye P.C.
Parkin Jeffrey
LandOfFree
Modified HIV-1 clade C envelope glycoprotein immunogens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified HIV-1 clade C envelope glycoprotein immunogens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified HIV-1 clade C envelope glycoprotein immunogens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254394